LMAT:NSD-LeMaitre Vascular Inc (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 84.72

Change

-1.56 (-1.81)%

Market Cap

USD 1.93B

Volume

0.15M

Analyst Target

USD 34.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It also provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular and porcine patches; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-21 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

-14.42 (-2.99%)

USD 161.79B
COO The Cooper Companies, Inc

-0.81 (-1.02%)

USD 15.49B
HOLX Hologic Inc

-0.62 (-1.08%)

USD 13.84B
ALGN Align Technology Inc

+0.81 (+0.47%)

USD 11.30B
RGEN Repligen Corporation

+1.64 (+1.26%)

USD 7.49B
MMSI Merit Medical Systems Inc

-1.29 (-1.42%)

USD 6.12B
ICUI ICU Medical Inc

-1.95 (-1.41%)

USD 3.43B
XRAY Dentsply Sirona Inc

-0.01 (-0.08%)

USD 2.70B
ATRC AtriCure Inc

-0.27 (-0.84%)

USD 1.70B
AZTA Azenta Inc

-0.22 (-0.87%)

USD 1.43B

ETFs Containing LMAT

VDHG:AU Vanguard Diversified High.. 2.95 % 0.00 %

N/A

USD 2.76B
XHE SPDR® S&P Health Care Eq.. 1.98 % 0.35 %

-1.08 (0.00%)

USD 0.16B
VDGR:AU Vanguard Diversified Grow.. 0.50 % 0.00 %

N/A

USD 0.79B
EWO iShares MSCI Austria ETF 0.00 % 0.47 %

-0.14 (0.00%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.05% 65% D 60% D-
Dividend Return 0.22% 25% F 8% B-
Total Return -7.84% 65% D 60% D-
Trailing 12 Months  
Capital Gain 34.97% 81% B- 88% B+
Dividend Return 1.08% 25% F 26% F
Total Return 36.05% 81% B- 87% B+
Trailing 5 Years  
Capital Gain 215.53% 93% A 90% A-
Dividend Return 9.78% 100% F 24% F
Total Return 225.31% 93% A 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 30.70% 86% B+ 83% B
Dividend Return 31.76% 86% B+ 83% B
Total Return 1.06% 40% F 27% F
Risk Return Profile  
Volatility (Standard Deviation) 37.58% 64% D 48% F
Risk Adjusted Return 84.53% 100% F 93% A
Market Capitalization 1.93B 79% B- 80% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.